Fractyl Health, Inc. (GUTS)
After hours:
| Previous Close | 4.4400 |
| Open | 4.4700 |
| Bid | 4.2900 x 400 |
| Ask | 4.3600 x 400 |
| Day's Range | 4.3000 - 4.4800 |
| 52 Week Range | 3.9800 - 14.5000 |
| Volume | |
| Avg. Volume | 174,019 |
| Market Cap | 206.915M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
GlobeNewswireFractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Company will discuss recent corporate updates, including compelling preclinical data from Rejuva® pancreatic gene therapy platform, which was named top abstract at American Diabetes Association’s 84th Scientific SessionBURLINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan, CEO
- GlobeNewswire
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1 cohort expected in Q4 2024 and mid-point data analysis for REMAIN-1 anticipated in Q2 2025 Company expands Revita type 2 diabetes clinical study REVITALIZE-1, expanding eligibility; increases potential U.S. treatment population for Revita by over 6x (from ~4 to ~25 million patients) Company presented preclinical data showing greater, more durable weight loss for its GLP-1 pancreatic gene the
- GlobeNewswire
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide withdrawal Data provide first demonstration that Rejuva treatment has potential to mimic natural release of GLP-1 from pancreas BURLINGTON, Mass., June 23, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approac
